NEW YORK, March 3, 2016 /PRNewswire-USNewswire/ -- Women who have acute migraine attacks that are severe enough to prompt them to seek care may be more likely to have complications when giving birth, including preterm delivery, preeclampsia and low birthweight. Women 35 and older were seven times more likely to have these complications.
"The results of this study were of particular interest because more than half of the pregnant women with migraine experienced some type of adverse birth outcome, suggesting that these pregnancies should be considered high risk," said study author Matthew S. Robbins, M.D., director of inpatient services at Montefiore Headache Center, chief of neurology at Jack D. Weiler Hospital of Montefiore, and associate professor of clinical neurology at Albert Einstein College of Medicine. "These findings need to be replicated with a larger number of women, including those who have migraine that does not manifest with severe attacks during pregnancy."
Acute migraine attacks are disabling headaches with symptoms that may include light and sound sensitivity, nausea, vomiting and visual disturbances.
Researchers reviewed five years of data at Montefiore and identified 90 women with severe migraine who sought emergency care while pregnant. The findings included:
- More than half of these women (54 percent) had at least one complication.
- Nearly 30 percent of the women had a preterm delivery, compared to nearly 10 percent in the general population.
- About 20 percent of the women with migraine had preeclampsia, a condition marked by high blood pressure, compared to between 5 and 8 percent in the general population.
- 19 percent of the women with migraine delivered babies with low birthweight, compared to 8 percent in the general population.
Most of the women with migraine, 62 percent, were treated with a combination of pill and intravenous (IV) drugs. Of those, 76 percent took acetaminophen, while 54 percent were given IV metoclopramide, a drug also prescribed for nausea, and 54 percent were given IV diphenhydramine, an antihistamine. It is not certain how the medications related to the outcomes in this study.
Additional Montefiore/Einstein study authors include Tracy Grossman, M.D. and Ashlesha Dayal, M.D.
About Montefiore Health System
Montefiore Health System is a premier academic health system and the University Hospital for Albert Einstein College of Medicine. Combining nationally-recognized clinical excellence with a population health perspective that focuses on the comprehensive needs of the communities it serves, Montefiore delivers coordinated, compassionate, science-driven care where, when and how patients need it most. Montefiore consists of eight hospitals and an extended care facility with a total of 2,747 beds, a School of Nursing, and state-of-the-art primary and specialty care provided through a network of more than 150 locations across the region, including the largest school health program in the nation and a home health program. The Children's Hospital at Montefiore is consistently named in U.S. News' "America's Best Children's Hospitals." Montefiore's partnership with Einstein advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. The health system derives its inspiration for excellence from its patients and community, and continues to be on the frontlines of developing innovative approaches to care. For more information please visit http://www.montefiore.org. Follow us on Twitter; like us on Facebook; view us on YouTube.
SOURCE Montefiore Health System